Sines

Researchers are evaluating whether eptinezumab can reduce the number of migraine days in children and adolescents aged 6 to 17 years with episodic migraine. The study is a randomized, double-blind, placebo-controlled trial designed to assess the preventive effects and safety of intravenous eptinezumab in this pediatric population. It is sponsored by H. Lundbeck AS and is conducted as a Phase 3 trial. Participants will be randomly assigned to receive one of three treatments a single weight-adjusted intravenous infusion of eptinezumab 300 mg, a single infusion of eptinezumab 100 mg, or a placebo infusion. The study compares these groups over the course of 12 weeks following the infusion to evaluate changes in migraine frequency and other related outcomes. During the study, participants and their caregivers will complete headache diaries to track migraine and headache days. Researchers will monitor changes in monthly migraine days averaged over weeks 1 to 12 as the primary outcome. Secondary measures include response rates at various thresholds, headache severity, medication use, and migraine disability scores. Blood samples will be collected at several time points to measure drug levels and immune response. The total participation includes baseline screening and 12 weeks of follow-up after the single infusion treatment.

Researchers are evaluating the long-term safety of eptinezumab in children and adolescents aged 6 to 17 years who have chronic or episodic migraine. This phase 3 open-label extension study includes participants who completed prior studies focused on chronic or episodic migraine treatment. The goal is to monitor safety outcomes over an extended period to better understand the effects of eptinezumab in this younger population. Participants will receive eptinezumab by intravenous infusion in one of two weight-adjusted dose groups 100 mg or 300 mg. Those who were previously assigned to a dose in the lead-in study will continue with the same dose, while those who received placebo will be randomly assigned to either dose group. Infusions are given at Weeks 0, 12, and 24 during the study. During the study, participants will be monitored through various assessments including blood tests for eptinezumab levels and antibodies, and a Pediatric Migraine Disability Assessment Questionnaire at multiple timepoints. Safety will be tracked from baseline up to Week 44 by recording any treatment emergent adverse events. The study lasts over several months, with follow-ups scheduled through Week 44 to evaluate long-term safety and impact on migraine-related disability.

Researchers are collecting data on adults with advanced non-small cell lung cancer NSCLC who have a specific genetic change called METex14 skipping alterations. This observational disease registry aims to track real-world treatment patterns, safety, and outcomes over time without changing the usual clinical care. The study is sponsored by EMD Serono Research Development Institute, Inc. and follows participants for up to about 4.9 years. Participants with advanced NSCLC receiving standard systemic therapies as decided by their doctors will be included in this registry. The study does not provide any specific treatments or procedures. Instead, it gathers information from routine clinical care starting at enrollment and continuing until death, loss to follow-up, enrollment in another clinical trial, or the registry ends. Throughout the study, researchers will collect data on tumor response using standard evaluations, overall survival, and any adverse events or reactions experienced by participants. Data collection occurs regularly for nearly five years, allowing the team to monitor changes in treatment and patient outcomes over time. This approach helps build a comprehensive picture of how patients with this lung cancer subtype are treated and how they fare in usual care settings.